Publication:
Impact of a multidisciplinary team for the management of thrombotic microangiopathy

dc.contributor.authorUriol Rivera, Miguel G
dc.contributor.authorCabello Pelegrin, Sheila
dc.contributor.authorBallester Ruiz, Maria del Carmen
dc.contributor.authorLópez Andrade, Bernardo
dc.contributor.authorLumbreras, Javier
dc.contributor.authorObrador-Mulet, Aina
dc.contributor.authorPerez Montana, Albert
dc.contributor.authorFerreruela Serlavos, Mireia
dc.contributor.authorAyestaran Rota, Jose Ignacio
dc.contributor.authorFerrer Balaguer, Juana Maria
dc.contributor.authorDelgado Sanchez, Olga
dc.contributor.authorPallares-Ferreres, Lucio
dc.contributor.authorMas Bonet, Antonio
dc.contributor.authorPicado Valles, Maria Jose
dc.contributor.authorRuiz de Gopegui, Rosa
dc.date.accessioned2024-09-06T09:56:40Z
dc.date.available2024-09-06T09:56:40Z
dc.date.issued2018-11-02
dc.description.abstractBackground: Thrombotic microangiopathy (TMA) is an important complication associated with several diseases that are rare and life-threatening. TMA is common to thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TTP is defined by a severe deficiency of ADAMTS13, and early treatment is associated with good prognosis. The diagnosis of HUS can be difficult due to the potential multiple etiologies, and the best treatment option in most cases is not well-established yet. The implementation of a multidisciplinary team (MDT) could decrease the time to diagnosis and treatment for HUS and may improve the outcomes of these patients. Objective: To determine the impact of MDT on morbidity and mortality [death or chronic renal replacement therapy (CRRT) requirements], incidence and response time [(RT) defined as the period between hospital admission and the first day of direct therapy administration], length of stay at an intensive care unit (ICU-LOS) and total hospitalization (T-LOS) were also assessed. Methods We compared a pre-MDT implementation period (from January/2008 to May/2016) versus post-MDT period (from May/2016 to December/2016). The screening TMA diagnosis was made according the following criteria: hemolytic anemia, thrombocytopenia and acute renal damage and without ADAMTS13 deficiency. An online chat was implemented to provide instant medical information. Results: Twenty-eight patients were included. The incidence changed from 2.3 cases/pre-MDT: (all cases: n = 18) to 10 cases/year post-MDT (all cases: n = 10). Two patients died in pre-MDT and post- MDT (11% versus 20%, P= 0.60). From pre-MDT, the number of patients who required CRRT by post-MDT decreased from 7 (39%) to 0, P= 0.03. Similarly, RT, ICULOS and T-LOS [median(p25-p75)] decreased from 10 (2-12) days to 0.5 (0-1.5) days, P= 0.04, from 16 (9-30) days to 10 (4-13) days, P= 0.01 and from 33 (22-53) days to 16 (1232) days, P < 0.01, respectively. Conclusion: MDT implementation was associated with a greater number of patients who meet TMA criteria. A decrease in the RT and T-LOS periods were observed and associated with better outcomes in these patients.en
dc.description.sponsorshipMGUR received travel grants and honoraria from Alexion Pharmaceuticals Inc. for speaking or participation at meetings and consultancy. SCP, MCBR, JL, JIAR, received travel grants and honoraria from Alexion Pharmaceuticals Inc. for speaking or participation at meetings. BLA, MJPV, MFS received travel grants Alexion Pharmaceuticals Inc. for participation at meetings. AMB also received travel grants Alexion Pharmaceuticals Inc. for participation at meetings. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.es_ES
dc.format.number11es_ES
dc.format.pagee0206558es_ES
dc.format.volume13es_ES
dc.identifier.citationUriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz MC, Lopez-Andrade B, Lumbreras Fernández J, Obrador Mulet A, et al. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One. 2018 Nov 02;13(11):e0206558.en
dc.identifier.doi10.1371/journal.pone.0206558
dc.identifier.issn1932-6203
dc.identifier.journalPloS Onees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/9030
dc.identifier.pubmedID30388144es_ES
dc.identifier.puiL624736664
dc.identifier.scopus2-s2.0-85056069800
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22610
dc.identifier.wos449289800042
dc.language.isoengen
dc.publisherPublic Library of Science (PLOS)
dc.relation.publisherversionhttps://dx.doi.org/10.1371/journal.pone.0206558en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.decsIncidencia*
dc.subject.decsResultado del Tratamiento*
dc.subject.decsTiempo de Tratamiento*
dc.subject.decsFemenino*
dc.subject.decsMasculino*
dc.subject.decsTiempo de Internación*
dc.subject.decsGrupo de Atención al Paciente*
dc.subject.decsHumanos*
dc.subject.decsAlgoritmos*
dc.subject.decsCuidados Críticos*
dc.subject.decsAdulto*
dc.subject.decsMicroangiopatías Trombóticas*
dc.subject.decsMejoramiento de la Calidad*
dc.subject.decsTerapia de Reemplazo Renal*
dc.subject.meshRenal Replacement Therapy*
dc.subject.meshAdult*
dc.subject.meshLength of Stay*
dc.subject.meshCritical Care*
dc.subject.meshHumans*
dc.subject.meshAlgorithms*
dc.subject.meshTime-to-Treatment*
dc.subject.meshMale*
dc.subject.meshQuality Improvement*
dc.subject.meshThrombotic Microangiopathies*
dc.subject.meshPatient Care Team*
dc.subject.meshFemale*
dc.subject.meshTreatment Outcome*
dc.subject.meshIncidence*
dc.titleImpact of a multidisciplinary team for the management of thrombotic microangiopathyen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationa2759e3d-0d58-4e8a-9fcd-c6130ee333d1
relation.isPublisherOfPublication.latestForDiscoverya2759e3d-0d58-4e8a-9fcd-c6130ee333d1

Files